drugset / Trial / NCT00219791
Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.
Timeline
- Start
- 2000-01
- Primary completion
- —
- Completion
- 2003-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucarpidase | Protein / enzyme biologic | 50 iu/kg | — |